SkinSpirit Launches PDRN Salmon DNA Regenerative Treatment
SEATTLE, July 1, 2026 SkinSpirit, a leading U.S. provider of medical aesthetic treatments, has expanded its regenerative aesthetics portfolio...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SEATTLE, July 1, 2026 SkinSpirit, a leading U.S. provider of medical aesthetic treatments, has expanded its regenerative aesthetics portfolio...
IRVINE, Calif., June 16, 2026 Allergan Aesthetics, an AbbVie company, has received U.S. Food and Drug Administration (FDA) approval...
North Chicago, Illinois, USA – May 21, 2026 Allergan Aesthetics, an AbbVie company and global leader in medical aesthetics,...
IRVING, Texas, April 9, 2026 Revision Skincare® has announced the publication of two peer-reviewed clinical studies in the Journal...
ZUG, Switzerland, January 29, 2026 — Galderma, the global pure-play dermatology leader, has unveiled ‘Wake Up To Restylane®’, a...
NEWPORT BEACH, California | January 9, 2026 — Evolus, Inc., a global performance beauty company specializing in aesthetic injectable...
